This company is no longer active
3MT Stock Overview
Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Magenta Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.70 |
| 52 Week High | US$1.88 |
| 52 Week Low | US$0.30 |
| Beta | 2.11 |
| 1 Month Change | -0.85% |
| 3 Month Change | 7.74% |
| 1 Year Change | -62.98% |
| 3 Year Change | -88.50% |
| 5 Year Change | -93.16% |
| Change since IPO | -94.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3MT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.7% | -5.1% | -2.0% |
| 1Y | -63.0% | -21.1% | -0.3% |
Return vs Industry: 3MT underperformed the German Biotechs industry which returned -7% over the past year.
Return vs Market: 3MT underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 3MT volatility | |
|---|---|
| 3MT Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3MT has not had significant price volatility in the past 3 months.
Volatility Over Time: 3MT's weekly volatility has decreased from 18% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 67 | n/a | www.magentatx.com |
Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company’s product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells.
Magenta Therapeutics, Inc. Fundamentals Summary
| 3MT fundamental statistics | |
|---|---|
| Market cap | €42.62m |
| Earnings (TTM) | -€63.95m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs 3MT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3MT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$68.70m |
| Earnings | -US$68.69m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.14 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 3MT perform over the long term?
See historical performance and comparison